Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease

• Published in: Scientific reports Vol. 7; no. 1; pp. 13713 - 11
• Main Authors: Vicente Miranda, Hugo, Cássio, Rafaela, Correia-Guedes, Leonor, Gomes, Marcos António, Chegão, Ana, Miranda, Elisa, Soares, Tiago, Coelho, Miguel, Rosa, Mário Miguel, Ferreira, Joaquim J, Outeiro, Tiago Fleming
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 20.10.2017; Nature Publishing Group UK
• Subjects: Aged; Aged, 80 and over; alpha-Synuclein - isolation & purification; alpha-Synuclein - metabolism; Axons; Biochemical markers; Biomarkers - blood; Blood; Clinical trials; Cohort Studies; Erythrocytes; Female; Humans; Lewy bodies; Male; Middle Aged; Movement disorders; Neurodegenerative diseases; Parkinson Disease - blood; Parkinson's disease; Protein Processing, Post-Translational; Synuclein
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-14175-5

Parkinson's disease (PD) is a progressive neurodegenerative disorder known for the typical motor features associated. Pathologically, it is characterized by the intracellular accumulation of alpha-synuclein (aSyn) in Lewy bodies and Lewy neurites. Currently, there are no established biochemical markers for diagnosing or for following disease progression, a major limitation for the clinical practice. Posttranslational modifications (PTMs) in aSyn have been identified and implicated on its pathobiology. Since aSyn is abundant in blood erythrocytes, we aimed to evaluate whether PTMs of aSyn in the blood might hold value as a biomarker for PD. We examined 58 patients with PD and 30 healthy age-matched individuals. We found that the levels of Y125 phosphorylated, Y39 nitrated, and glycated aSyn were increased in PD, while those of SUMO were reduced. A combinatory analysis of the levels of these PTMs resulted in an increased sensitivity, with an area under curve (AUC) of 0.843 for PD versus healthy controls, and correlated with disease severity and duration. We conclude that the levels of these selected PTMs hold strong potential as biochemical markers for PD. Ultimately, our findings might facilitate the monitoring of disease progression in clinical trials, opening the possibility for developing more effective therapies against PD.